We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR Newswire LUND, Sweden, July 17, 2023 Favorable safety...
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR Newswire LUND, Sweden, July 17, 2023 Favorable safety...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023 Brixadi is the first treatment for opioid use...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023 Brixadi is the first treatment for opioid use...
Braeburn receives new Complete Response Letter for Brixadi in the US PR Newswire LUND, Sweden, Dec. 15, 2021 LUND, Sweden, Dec. 15, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today...
FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease PR Newswire LUND, Sweden, Sept. 16, 2021 LUND, Sweden, Sept. 16, 2021 /PRNewswire/...
FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease PR Newswire LUND, Sweden, Sept. 16, 2021 LUND, Sweden, Sept. 16, 2021 /PRNewswire/...
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US PR Newswire LUND, Sweden, June 26, 2021 New PDUFA action date for Brixadi set for 15 December 2021...
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US New PDUFA action date for Brixadi set for 15 December 2021 PR Newswire LUND, Sweden, June 26, 2021...
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire LUND, Sweden, June 15, 2021 LUND, Sweden, June 15, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 101.2 | 101.2 | 101.2 | 2351 | 101.2 | DE |
4 | 0 | 0 | 101.2 | 101.2 | 101.2 | 5916 | 101.2 | DE |
12 | 0 | 0 | 101.2 | 101.2 | 101.2 | 7451 | 101.2 | DE |
26 | 0 | 0 | 101.2 | 101.2 | 101.2 | 7689 | 101.2 | DE |
52 | 0 | 0 | 101.2 | 101.2 | 101.2 | 15383 | 101.2 | DE |
156 | 0 | 0 | 101.2 | 101.2 | 101.2 | 10700 | 101.2 | DE |
260 | 0 | 0 | 101.2 | 101.2 | 101.2 | 7484 | 101.2 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions